Naegelin Y, Dingsdale H, Suberli K, Schdelin S, Kappos L, Barde YA
However, it is important to understand that 24 weeks, while substantial for clinical trials, provides limited information about safety with years-long continuous use
While most Canadian physicians have limited familiarity with research peptides, some naturopathic doctors and integrative medicine practitioners have experience with these compounds
They are not FDA-approved and have not gone through the review process applied to brand-name drugs
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH)
For intranasal administration, commonly reported empirical dosing includes 100-200 mcg per nostril taken once or twice daily (obviously, BPC-157 should first be reconstituted in bacteriostatic water at an appropriate concentration for nasal delivery)